Lp(a): Evidence-Based Ways to Improve This Number

What Is Lp(a) and Why Does It Matter?

Lipoprotein(a) is a low-density lipoprotein particle with an extra protein, apolipoprotein(a), covalently bonded to its apolipoprotein B-100 component. This added protein gives Lp(a) prothrombotic and proinflammatory properties that standard LDL particles lack. The result is a cardiovascular risk factor that operates independently of your LDL-C number.

A 2009 meta-analysis of 36 prospective studies (N=126,634) published in JAMA found that individuals in the top third of Lp(a) concentration had a 1.6-fold higher risk of coronary heart disease compared with those in the bottom third, after adjustment for traditional risk factors [1]. The European Atherosclerosis Society (EAS) consensus statement from 2010, updated in 2022, identifies Lp(a) above 50 mg/dL (approximately 125 nmol/L) as the threshold conferring clinically meaningful risk [2]. This threshold applies across sex and ethnicity, though absolute concentrations vary by ancestry. Black individuals, on average, carry Lp(a) levels roughly two to three times higher than white individuals, a finding replicated in the Dallas Heart Study and MESA cohorts [3].

Because the LPA gene on chromosome 6 controls roughly 90% of circulating Lp(a) levels, a single measurement is generally sufficient for risk stratification [2]. Repeat testing is useful only when a patient starts Lp(a)-lowering therapy and needs to confirm response.

Understanding Your Lp(a) Number

Your lab result will appear in one of two units: mg/dL or nmol/L. The distinction matters because there is no reliable universal conversion factor between them.

The difference stems from the variable size of the apolipoprotein(a) isoform. A patient with small apo(a) isoforms can have a higher particle number at a given mass concentration than a patient with large isoforms. The EAS recommends reporting in nmol/L when possible for more accurate risk assessment [2]. Many U.S. labs still report mg/dL, so clinicians commonly use these approximate cutoffs:

• Desirable: below 30 mg/dL (below 75 nmol/L)
• Borderline: 30 to 50 mg/dL (75 to 125 nmol/L)
• High risk: above 50 mg/dL (above 125 nmol/L)

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias recommend measuring Lp(a) at least once in every adult's lifetime to identify those with very high inherited levels above 180 mg/dL (above 430 nmol/L), a level that confers a lifetime risk of atherosclerotic cardiovascular disease comparable to heterozygous familial hypercholesterolemia [4]. A low Lp(a), by contrast, is reassuring. Values below 10 mg/dL carry no known cardiovascular penalty. There is no clinical reason to raise a low Lp(a).

Why Lp(a) Is Difficult to Lower

Lp(a) resists the interventions that reliably reduce LDL-C. Statins, the backbone of lipid-lowering therapy, either do not change Lp(a) or raise it slightly by 10 to 20%, a finding documented in a 2012 systematic review of 5,256 patients across multiple randomized trials [5]. The mechanism appears related to statin-induced upregulation of LPA gene transcription, though this increase has not been linked to worse outcomes in statin-treated patients.

Diet and aerobic exercise show little consistent effect on Lp(a). A 2019 review in Atherosclerosis examined controlled feeding studies and exercise interventions and found no reproducible reduction exceeding 10% from lifestyle changes alone [6]. This stands in sharp contrast to LDL-C and triglycerides, both of which respond meaningfully to dietary modification.

The reason is straightforward. Lp(a) is produced in the liver at a rate determined almost entirely by genetics. Its clearance pathway remains incompletely characterized, which is why so few existing drugs affect it.

PCSK9 Inhibitors: The Current Best Pharmacologic Option

Evolocumab (Repatha) and alirocumab (Praluent) lower Lp(a) by approximately 20 to 30% as a secondary effect of their primary LDL-C reduction [7]. The FOURIER trial (N=27,564) showed that evolocumab reduced Lp(a) by a median of 26.9% and that patients with higher baseline Lp(a) derived greater absolute cardiovascular benefit from therapy [7].

A prespecified analysis of FOURIER, published in Circulation in 2019, found that each 25 nmol/L reduction in Lp(a) with evolocumab was associated with a 3% lower risk of major adverse cardiovascular events, independent of LDL-C lowering [7]. This result provides some of the strongest existing evidence that pharmacologic Lp(a) reduction translates into clinical benefit.

PCSK9 inhibitors are FDA-approved for LDL-C lowering, not for Lp(a) reduction specifically. Prescribing them primarily for Lp(a) remains off-label but is considered reasonable by multiple lipid specialists when a patient carries both high Lp(a) and elevated LDL-C. "For patients with Lp(a) above 50 mg/dL and established ASCVD, adding a PCSK9 inhibitor addresses two risk factors simultaneously," notes the 2019 NLA Scientific Statement on Lp(a) [8].

Niacin: Effective on Paper, Disappointing in Outcomes

Extended-release niacin (1 to 2 g/day) lowers Lp(a) by 20 to 30%, the largest reduction of any widely available oral medication [9]. This effect has been replicated across multiple trials.

The problem is outcomes data. Two large randomized trials tested niacin added to statin therapy and found no reduction in cardiovascular events. AIM-HIGH (N=3,414) was stopped early for futility in 2011 [10]. HPS2-THRIVE (N=25,673) showed no benefit and documented excess serious adverse events including new-onset diabetes, gastrointestinal effects, and musculoskeletal complaints [11]. Neither trial was designed to test Lp(a) lowering specifically, and their populations were not enriched for high Lp(a). Still, the results have dampened enthusiasm for niacin as a primary Lp(a) strategy.

The AHA/ACC guidelines do not recommend niacin for Lp(a) reduction outside of clinical trials. Some lipidologists continue to prescribe it selectively in patients with very high Lp(a) and progressive atherosclerosis, accepting the side-effect profile when the alternative is no treatment.

Antisense and siRNA Therapies: The Pipeline That Could Change Everything

The most promising Lp(a)-lowering agents target hepatic production of apolipoprotein(a) at the mRNA level. Two drug classes are in advanced development: antisense oligonucleotides (ASOs) and small interfering RNA (siRNA).

Pelacarsen (TQJ230)

Pelacarsen is a GalNAc-conjugated ASO developed by Novartis (originally Ionis/Akcea) that binds LPA mRNA in hepatocytes and prevents apolipoprotein(a) synthesis. In a Phase 2 trial (N=286) published in JAMA in 2020, monthly subcutaneous injections of pelacarsen 60 mg reduced Lp(a) by approximately 80% from baseline compared with placebo [12].

The Phase 3 cardiovascular outcomes trial, Lp(a)HORIZON (NCT04023552), enrolled approximately 8,323 patients with established cardiovascular disease and Lp(a) above 70 mg/dL. The trial is designed to determine whether Lp(a) reduction with pelacarsen lowers the rate of major adverse cardiovascular events [13]. Results are expected in 2026 or 2027. If positive, pelacarsen could become the first drug approved specifically for Lp(a) lowering with an outcomes indication.

Olpasiran

Olpasiran is a GalNAc-conjugated siRNA developed by Amgen that silences LPA mRNA through the RNA interference pathway. The Phase 2 OCEAN(a)-DOSE trial (N=281), published in The New England Journal of Medicine in 2023, showed dose-dependent Lp(a) reductions of 70.5% to 101.1% at 36 weeks, with the highest dose (225 mg every 12 weeks) achieving near-complete elimination of circulating Lp(a) [14].

The large Phase 3 outcomes trial, OCEAN(a)-Outcomes (NCT05581303), is enrolling approximately 6,000 patients and will evaluate whether this degree of Lp(a) suppression reduces cardiovascular events.

Lepodisiran and Zerlasiran

Other siRNA candidates are progressing. Lepodisiran (Eli Lilly), tested in a Phase 1 study published in JAMA in 2023, reduced Lp(a) by up to 97% with effects persisting for over 48 weeks after a single dose [15]. Zerlasiran (Silence Therapeutics) showed similar potency in early-phase data.

The pipeline, taken together, suggests that within the next two to four years, clinicians may have multiple options for near-complete Lp(a) suppression. The remaining question is whether the surrogate endpoint (Lp(a) reduction) translates into fewer heart attacks and strokes.

Lipoprotein Apheresis: A Last-Resort Physical Removal

For patients with very high Lp(a) (above 60 mg/dL) and progressive cardiovascular disease despite maximally tolerated lipid therapy, lipoprotein apheresis can acutely reduce Lp(a) by 60 to 75% per session [16]. The procedure, performed every one to two weeks, filters Lp(a) and LDL particles from the blood in a process similar to dialysis.

Germany's national guidelines have approved apheresis for isolated Lp(a) elevation with progressive ASCVD since 2008, and retrospective data from the German Lipoprotein Apheresis Registry (N=170) showed a 78% reduction in major adverse cardiovascular events after initiation [16]. In the United States, insurance coverage for apheresis based solely on Lp(a) remains inconsistent, and the FDA has not established a formal indication for it.

Apheresis is time-intensive and expensive. Sessions take two to four hours, and levels rebound within days. It serves as a bridge therapy for the highest-risk patients awaiting definitive pharmacologic options.

What You Can Control: Addressing the Full Risk Picture

Because Lp(a) itself resists lifestyle modification, the most effective strategy for patients with elevated Lp(a) is aggressive management of every other modifiable cardiovascular risk factor. Think of high Lp(a) as raising your baseline risk floor. The clinical job is to lower every other variable as far as possible.

LDL-C reduction is the highest-yield intervention. The 2018 AHA/ACC Cholesterol Guideline recommends treating high-risk patients to an LDL-C below 70 mg/dL, or below 55 mg/dL per ESC/EAS targets, using high-intensity statins with ezetimibe or PCSK9 inhibitors as needed [17]. For a patient with Lp(a) above 50 mg/dL and established ASCVD, the PCSK9 inhibitor route offers the dual benefit of substantial LDL-C reduction and modest Lp(a) lowering.

Blood pressure, glucose, smoking, and body weight all respond to intervention and compound cardiovascular risk when left uncontrolled alongside high Lp(a). A 2020 analysis from the UK Biobank (N=413,734) demonstrated that among participants with Lp(a) in the top quintile, those who maintained four or more healthy lifestyle factors (non-smoking, BMI <25, regular exercise, healthy diet) had a 45% lower risk of coronary events than those with zero to one healthy factors [18].

The takeaway is practical. You cannot diet your way to a lower Lp(a). You can diet, exercise, and medicate your way to a substantially lower total cardiovascular risk despite a high Lp(a).

Supplements and Alternative Approaches: What the Evidence Shows

Several supplements have been studied for Lp(a) reduction, but none has strong enough evidence to earn guideline endorsement.

L-carnitine showed a 14% Lp(a) reduction in a small meta-analysis of 4 RCTs (N=292) published in Clinical Nutrition in 2016 [19]. The studies were short (8 to 24 weeks), and cardiovascular outcomes were not assessed.

Coenzyme Q10 has minimal evidence for Lp(a) lowering. A 2018 meta-analysis in Pharmacological Research of 8 trials found no significant change in Lp(a) with CoQ10 supplementation [20].

Flaxseed was tested in a small crossover trial and showed a 14% Lp(a) reduction, but larger confirmatory data are lacking.

Aspirin at 325 mg/day reduced Lp(a) by approximately 18 to 23% in two small studies from the 1990s, but the mechanism is unclear, and no guideline recommends aspirin specifically for Lp(a) lowering [21].

None of these approaches should replace established pharmacotherapy. Patients interested in supplements should discuss them with their prescribing clinician, particularly given potential drug interactions.

Hormonal Therapies and Lp(a)

Estrogen-containing hormone therapy lowers Lp(a) by 20 to 25% in postmenopausal women, a consistent finding across observational and trial data including the Women's Health Initiative [22]. Testosterone replacement in hypogonadal men has shown more variable effects, with some studies reporting 10 to 15% reductions and others showing no change.

These therapies are prescribed for their primary indications (menopausal symptoms, symptomatic hypogonadism), not for Lp(a) management. But the Lp(a)-lowering effect is worth noting when weighing the cardiovascular risk-benefit ratio in patients already considering hormone therapy for other reasons.

DHEA supplementation has shown modest Lp(a) reductions (10 to 15%) in small studies of postmenopausal women, but data quality is limited and no clinical society recommends DHEA for this purpose.

When to Retest and How to Monitor

The EAS consensus panel recommends a single lifetime Lp(a) measurement for cardiovascular risk stratification [2]. Retesting is appropriate in three scenarios:

1. After starting a PCSK9 inhibitor, to confirm the expected 20 to 30% reduction and assess whether the residual level remains high enough to warrant additional therapy.
2. If enrolling in a clinical trial for pelacarsen, olpasiran, or another Lp(a)-targeted agent, serial measurements will be part of the study protocol.
3. Family cascade screening, when a first-degree relative is found to have Lp(a) above 50 mg/dL, all siblings and children should be tested once.

Repeated testing outside these situations adds cost without changing management, since the genetically fixed nature of Lp(a) means levels remain stable over decades in the absence of targeted treatment.

Clinicians should confirm that their lab uses an isoform-insensitive assay, as older turbidimetric assays can overestimate Lp(a) in patients with small apo(a) isoforms. The WHO/IFCC reference material (SRM 2B) standardizes results across platforms [2].